Sign in
Taking people in United StatesPhase 2

Tests on-and-off relugolix with ARPI for prostate cancer that has spread

Tests stopping and restarting relugolix with ARPI in adults with spreading prostate cancer.

Key facts

Who runs it
University of Utah
Where
Salt Lake City, United StatesSee the site
Trial code
Registry title
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
Status
Recruiting
Phase
Phase 2
People taking part
160 people, planned
Started
28 Oct 2025
Expected to end
Oct 2031
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • relugolix + ARPI
  • Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI
  • relugolix or androgen deprivation therapy (ADT) + ARPI
  • relugolix + ARPI.
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread and still responds to hormone treatment, with a very low PSA after treatment. It tests on-and-off relugolix with an ARPI.

Age
18 years or older
Sex
Men only
Disease stage
Prostate cancer (adenocarcinoma, no small cell type) that has spread to other parts of the body and responds to hormone treatment. Daily activity level (ECOG) of 2 or lower in cohort A.
Earlier treatment
Cohort A: PSA of 0.2 ng/mL or lower after 6-12 months of relugolix plus an ARPI. Cohort B: PSA of 0.2 ng/mL or lower after hormone-blocking treatment, an ARPI, or both, of any length. In cohort A, no earlier leuprolide or surgical castration for spread cancer.
Biomarker or test result
Cohort A: testosterone above 50 ng/dl and PSA of 1 ng/mL or higher before treatment for spread cancer. PSA of 0.2 ng/mL or lower after treatment, as above.

Main reasons for not taking part

  • Other systemic cancer treatment for prostate cancer
  • Cancer that no longer responds to castration (cohort A, step 2)
  • Another cancer that could affect safety or taking part
  • Known brain metastases or cranial epidural disease, unless treated and stable
  • Previous surgical castration (cohort B)

The registry criteria, word for word

Show all 41 criteriaShow less

Who can take part

  • Cohort A Eligibility (Step 1 Registration)
  • Participant aged ≥ 18 years
  • Hormone-sensitive prostate cancer with histologically/cytologically confirmed adenocarcinoma without small cell histology
  • Metastasis detected any time prior to study registration on conventional or functional imaging as determined by the treating investigator and can be of any site
  • Baseline testosterone >50 ng/dl before start of therapy for metastatic disease
  • PSA ≥ 1 ng/mL before start of therapy for metastatic disease
  • ECOG Performance Status ≤ 2
  • Eligible to receive standard of care treatment with relugolix and APRI per clinical investigator
  • Participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception requirements as described in Section 5.5.1; If the risk of seminal transfer from the participant is present, the participant must agree to use a condom during sexual intercourse as described in Section 5.5.2; Participants must agree not to donate sperm from the start of study therapy until 3 months after the last dose of study therapy
  • Clinically significant adverse effects from any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy) must have resolved or have been determined to be clinically stable per the Investigator
  • Has access to a smartphone and wireless services and is able to download and navigate study specific applications
  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines; Cohort A Eligibility (Step 2 Registration):
  • PSA ≤ 0.2 ng/mL after 6-12 months of relugolix and androgen receptor pathway inhibitor treatment. Androgen receptor pathway inhibitor includes abiraterone, enzalutamide, apalutamide, darolutamide or similar drugs; Cohort B Eligibility
  • Participant aged ≥ 18 years
  • Hormone-sensitive prostate cancer with histologically/cytologically confirmed adenocarcinoma without small cell histology
  • Metastasis detected any time prior to study registration on conventional or functional imaging as determined by clinical investigator and can be of any site
  • PSA ≤ 0.2 ng/mL after treatment with androgen deprivation therapy or androgen receptor pathway inhibitor treatment or both of any duration. Androgen deprivation therapy in this context includes gonadotropin-releasing hormone agonists and antagonists. Androgen receptor pathway inhibitors include abiraterone, enzalutamide, apalutamide, darolutamide or similar drugs
  • Eligible to receive standard of care treatment with relugolix and APRI per clinical investigator
  • Participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception requirements as described in Section 5.5.1; If the risk of seminal transfer from the participant is present, the participant must agree to use a condom during sexual intercourse as described in Section 5.5.2; Participants must agree not to donate sperm from the start of study therapy until 3 months after the last dose of study therapy
  • Has access to a smartphone and wireless services and is able to download and navigate study specific applications
  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines

Who cannot take part

  • Participant received androgen deprivation therapy (defined as leuprolide or surgical castration) for metastatic hormone-sensitive prostate cancer
  • Known brain metastases or cranial epidural disease; --Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Participants must be neurologically stable and receiving a stable or decreasing corticosteroid dose at the time of study entry
  • Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3)
  • Participants taking prohibited medications as described in Section 6.6.2; Cohort A Eligibility (Step 2 Registration)
  • Receiving other systemic anti-cancer therapy for prostate cancer. Prior treatment before Step 2 registration is allowed
  • Participants taking prohibited medications as described in Section 6.6.2; Cohort B Eligibility
  • Receiving other systemic anti-cancer therapy for prostate cancer
  • Known brain metastases or cranial epidural disease; --Note: Brain metastases or cranial epidural disease adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Participants must be neurologically stable and receiving a stable or decreasing corticosteroid dose at the time of study entry
  • Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3)
  • Participants taking prohibited medications as described in Section 6.6.1
  • The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study
  • Current evidence of uncontrolled, significant intercurrent illness, infection, non-compliance or other safety concerns which may affect clinical trial participation
  • Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study
  • Progression to metastatic castration-resistant prostate cancer per clinical investigator
  • The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study
  • History of surgical castration
  • The diagnosis of another malignancy which, in the opinion of the Investigator, is likely to negatively impact the participant's safety or ability to participate in the study
  • Current evidence of uncontrolled, significant intercurrent illness, infection, compliance or other safety concerns which may affect clinical trial participation
  • Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study
  • Cohort A Eligibility (Step 1 Registration)

Where in United States

  • Huntsman Cancer Institute at University of UtahSalt Lake City, United StatesContact: Erynn PeytonTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

The 3 groups in the trial

  • Cohort A: Arm 1Existing treatment, for comparison

    INDUCTION (Step 1): Participants will receive continuous treatment with relugolix + an androgen receptor pathway inhibitor (ARPI). After 6-12 months of continuous treatment, participants whose PSA is ≤ 0.2 ng/mL and who have completed step two registration will be randomized to one of two treatment arms: • Cohort A: Arm 1 will continue standard-of-care, continuous treatment with relugolix or androgen deprivation therapy (ADT) + ARPI per clinical investigator.

    Treatment: relugolix + ARPI and relugolix or androgen deprivation therapy (ADT) + ARPI

  • Cohort A: Arm 2Treatment being tested

    INDUCTION (Step 1): Participants will receive continuous treatment with relugolix + an androgen receptor pathway inhibitor (ARPI). After 6-12 months of continuous treatment, participants whose PSA is ≤ 0.2 ng/mL and who have completed step two registration will be randomized to one of two treatment arms: • Cohort A: Arm 2 will receive intermittent treatment with relugolix + ARPI.

    Treatment: relugolix + ARPI and relugolix + ARPI.

  • Cohort BTreatment being tested

    Participants who have achieved PSA ≤ 0.2 ng/mL are eligible and will receive intermittent treatment with relugolix + ARPI.

    Treatment: Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase II Randomized, Decentralized, De-escalation Study in Patients With Metastatic Hormone-Sensitive Prostate Cancer Achieving Optimal PSA Response (OPTIMAS)
Plain-language title
Tests on-and-off relugolix with ARPI for prostate cancer that has spreadGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 November 2026